NADIM-ADJUVANT: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
Status:
Recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial.
210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled
in this trial to evaluate the disease free survival between experimental arm (Adjuvant
Chemotherapy-Immunotherapy + maintenance adjuvant Immunotherapy) and control arm (Adjuvant
Chemotherapy)